The need for individualised antipsychotic drug therapy in patients with schizophrenia

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue 6, 2009, Pages 453-459

  Pani, Luca ^a  

^a Technological Park of Sardinia 'Sardegna Ricerche'   (Italy)

Author keywords

Antipsychotics; Cluster analysis; Mediators; Moderators; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE;

AGE DISTRIBUTION; AMBIVALENCE; BIPOLAR DISORDER; CLINICAL TRIAL; CLUSTER ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ETHNIC GROUP; EXTRAPYRAMIDAL SYMPTOM; FAMILY CONFLICT; GENDER; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEREDITY; HUMAN; MENTAL PATIENT; METABOLIC DISORDER; NEGATIVE SYNDROME; OBESITY; PATIENT; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PHYSICIAN; POLYPHARMACY; POSITIVE SYNDROME; PRESCRIPTION; RACE; REMISSION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; SOCIAL STRESS; STEADY STATE; SYMPTOM; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; INDIVIDUALIZED MEDICINE; SCHIZOPHRENIA;

EID: 74949113657     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. ) NOEL JM. ASHP therapeutic position statement on the use of second-generation antipsychotic medications in the treatment of adults with psychotic disorders. Am J Health Syst Pharm 2007; 64: 863-876.
2. TANDON R, KESHAVAN MS, NASRALLAH HA. Schizophrenia, just the facts: what we know in 2008 part 1 : overview. Schizophr Res 2008; 100: 4-19.
3. APA. Schizophrenia and other psychotic disorders. 4th ed. Washington DC: American Psychiatric Press; 2000.
4. KAY SR, FISZBEIN A OPLER LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 2007; 13: 261-276.
5. LEHMAN AE LIEBERMAN JA DIXON LB, MCGLASHAN TH, MILLER AL PERKINS DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiat 2004; 161(2 Suppl): 1-56.
6. GRANT BF STINSON FS, HASIN DS, DAWSON DA, CHOU SR RUAN WJ, et al. Prevalence, correlates, and co morbidity of bipolar I disorder and axis I and II disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry 2005; 66: 1205-1215.
7. KESSLER RC, MCGONAGLE KA, ZHAO S, NELSON CB, HUGHES M, ESHLEMAN S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19.
8. WEIDEN PJ, PRESKORN SH, FAHNESTOCK PA CARPENTER D, ROSS R, DOCHERTY JP. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiatry 2007; 68(Suppl 7): 1-48.
9. CONLEY RR, KELLY DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 2005; 42: 51-60.
10. DERRY S, MOORE RA. Atypical antipsychotics in bipolar disorder: systematic review of randomised trials. BMC Psychiatry 2007; 7: 40.
11. ) PIERRE JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Safety 2005; 28: 191-208.
12. WEIDEN PJ. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 2006; 20: 104-119.
13. EMSLEY RA. Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 1999; 60(Suppl 23): 10-13.
14. LIEBERMAN JA, STROUP TS, MCEVOY JP, SWARTZ MS, ROSENHECK RA, PERKINS DO, KEEFE RS, DAVIS SM, DAVIS CE, LEBOWITZ BD, SEVERE J, HSIAO JK; CLINICAL ANTIPSYCHOTIC TRIALS OF INTERVENTION EFFECTIVENESS (CATIE) INVESTIGATORS. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
15. KRAEMER HC, WILSON GT, FAIRBURN CG, AGRAS WS. Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 2002; 59: 877-883.
16. GOLDSTEIN G, SANDERS RD, FORMAN SD, TARPEY T, GURKUS JA VAN KÄMMEN DP KESHAVAN MS. The effects of antipsychotic medication on factor and cluster structure of neurologic examination abnormalities in schizophrenia. Schizophr Res 2005; 75: 55-64.
17. HARTIGAN J. Clustering algorithms. New York: Wiley; 1975.
18. HELMES E, LANDMARK J. Subtypes of schizophrenia: a cluster analytic approach. Can J Psychiatry 2003; 48: 702-708.
19. HOTI F, TUULIO-HENRIKSSON A, HAUKKA J, PARTOEN T, HOLMSTROM LJL. Family-based clusters of cognitive test performance in familial schizophrenia. BMC Psychiatry 2004; 4: 1-13.
20. Lencz T, Raine A, Sheard C. Neuroanatomical bases of electrodermal hypo-responding: a cluster analytic study. Int. J Psychophysiol 1996; 665.
21. ) SANTONE G, RUCCI P, MURATORI ML, MONACI A, CIARAFONI C, BORSETTI G. Attitudes toward medication in inpatients with schizophrenia: a cluster analytic approach. Psychiatry Res 2008; 158: 324-334.
22. LEUNG A, CHUE P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000; 401: 3-38.
23. SZYMANSKI S, LIEBERMAN JA, ALVIR JM, MAYERHOFF D, LOEBEL A, GEISLER S, CHAKOS M, KOREEN A, JODY D, KANE J, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995; 152: 698-703.
24. THOMPSON PM, VIDAL C, GIEDD JN, GOCHMAN P, BLUMENTHAL J, NICOLSON R, TAGA AW RAPOPORT JL. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 11650-11655.
25. BJERRUM L, SOGAARD J, HALLAS J, KRAGSTRUP J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54: 197-202.
26. KIM E, LEVY R, PIKALOV A. Personalized treatment with atypical antipsychotic medications. Adv Ther 2007; 24: 721-740.
27. GIANFRANCESCO FD, RAJAGOPALAN K, SAJATOVIC M, WANG RH. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006; 67: 222-232.
28. SAJATOVIC M, VALENSTEIN M, BLOW FC, GANOCZY D, IGNACIO RV. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8: 232-241.
29. LINGHAM R, SCOTT J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105: 164-172.
30. DIAZ FJ, DE LEON J. Excessive antipsychotic dosing in 2 U.S. State hospitals. J Clin Psychiatry 2002; 63: 998-1003.
31. SEGAL SP, BOLA JR, WATSON MA. Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Serv 1996; 47: 282-286.
32. WALKUP JT, MCALPINE DD, OLFSON M, LABAY LE, BOYER C, HANSELL S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000; 61: 344-348.
33. WHEELER A, HUMBERSTONE V, ROBINSON E. Ethnic comparisons of antipsychotic use in schizophrenia. Aust N Z J Psychiatry 2008; 42: 863-873.
34. KANE JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 2001; 11 (Suppl. 4): S397-403.
35. ALLISON DB, MENTORE JL, HEO M, CHANDLER LP, CAPPEL-LERI JC, INFANTE MC, WEIDEN PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
36. AMERICAN DIABETES ASSOCIATION. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-272.
37. MILL J, TANG T, KAMINSKY Z, KHARE T, YAZDANPANAH S, BOUCHARD L, JIA P, ASSADZADEH A, FLANAGAN J, SCHUMACHER A, WANG SC, PETRONIS A. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82: 696-711.
38. MÜLLER DJ, MUGLIA P, FORTUNE T, KENNEDY JL. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacol Res 2004; 49: 309-329.
39. REYNOLDS GP, ZHANG ZJ, ZHANG XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002; 359: 2086-2087.
40. SERRETTI A, MANDELLI L. The genetics of bipolar disorder: genome "hot regions", genes, new potential candidates and future directions. MoI Psychiatry 2008; 13: 742-771.
41. NASRALLAH HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008; 13: 27-35.
42. ARRANZ MJ, MUNRO J, BIRKETT J, BOLONNA A, MANCAMA D, SODHI M, LESCH KP, MEYER JF, SHAM P, COLLIER DA, MURRAY RM, KERWIN RW. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-1616.
43. SERRETTI A, KATO M, KENNEDY JL. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 2008; 8: 90-100.
44. SWARTZ MS, STROUP TS, MCEVOY JP, DAVIS SM, ROSENHECK RA, KEEFE RS, HSIAO JK, LIEBERMAN JA. What CATIE found: results from the schizophrenia trial. Psychiatry Serv 2008; 59: 500-506.
45. MANSCHRECK TC, BOSHES RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007; 15: 245-258.
46. KAPUR S, REMINGTON G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50: 873-883.
47. PANI L, PIRA L, MARCHESE G. Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry 2007; 22: 267-275.
48. SHARIF ZA. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in special populations. Primary Care Companion J Clin Psychiatry 2003; 5(Suppl 6): 22-25.
49. KAPUR S, ZIPURSKY R, JONES C. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
50. HIEMKE C, DRAGICEVIC A, GRÜNDER G, HÄTTER S, SACHSE J, VERNALEKEN I, MÜLLER MJ. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160.
51. ANANTH J, PARAMESWARAN S, GUNATILAKE S. Antipsychotic polypharmacy. Curr Pharm Des 2004; 10: 2231-2238.
52. STAHL SM, GRADY MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004; 11: 313-327.
53. DEQUARDO JR, ROBERTS M. Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 1996; 153: 840-841.
54. HIEMKE C, WEIGMANN H, HARTTER S, DAHMEN N, WETZEL H, MÜLLER H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-281.
55. JERLING M, LINDSTROM L, BONDESSON U, BERTILSSON L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-374.
56. KOPONEN HJ, LEINONEN E, LEPOLA U. Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 1996; 6: 69-71.
57. MARKOWITZ JS, GILL HS, LAVIA M, BREWERTON TD, DEVANE CL. Fluvoxamine-clozapine dose-dependent interaction. Can J Psychiatry 1996; 41: 670-671.
58. DIKEOS DG, WICKHAM H, MCDONALD C, WALSHE M, SIGMUNDSSON T, BRAMON E, GRECH A, TOULOPOULOU T, MURRAY R, SHAM PC. Distribution of symptom dimensions across Kraepelinian divisions. Br J Psychiatry 2006; 189: 346-353.
59. RICHELSON E. Preclinical pharmacology of neuroleptics: focus on new generation compounds. J Clin Psychiatry 1996; 57(Suppl 11): 4-11.
60. SEEGER TF, SEYMOUR PA, SCHMIDT AW, ZORN SH, SCHULZ DW, LEBEL LA, MCL EAN S, GUANOWSKY V, HOWARD HR, LOWE JA 3RD, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-113.
61. ) WESTERINK BH, KAWAHARA Y, DE BOER P, GEELS C, DE VRIES JB, WIKSTRÖM HV, VAN KALKEREN A, VAN VLIET B, KRUSE CG, LONG SK. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001; 412: 127-138.
62. MAURI MC, VOLONTERI LS, COLASANTI A, FIORENTINI A, DE GASPARI IF BAREGGI SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359-388.